Compare Moderna, Inc. (MRNA) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Tyson Foods, Inc. — how do they compare? Moderna, Inc. trades at $136.8 (market cap $54.14B), while Tyson Foods, Inc. trades at $51.97 (market cap $18.20B). The key difference: Moderna, Inc. is far larger — about 3× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays a 3.94% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | TSN | |
|---|---|---|
Market Cap | $54.14B | $18.20B |
Sector | Health | Consumer Staples |
52-Week High | $174.38 | $68.75 |
52-Week Low | $22.36 | $50.72 |
Enterprise Value | $50.29B | $25.47B |
Dividend Yield | — | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Tyson Foods (TSN) trades at $52.28, up 1.67% today, with mixed technical signals showing bearish moving averages but oversold RSI levels. Fundamentally, the company reported Q2 2026 EPS of $0.99 beating expectations, though revenue growth guidance was recently cut to 1.5%-2.0% for fiscal 2026 due to beef segment pressures. Valuation metrics show a P/E of 32.27 and P/S of 0.33, with analyst consensus leaning bullish despite recent negative news flow.
The stock presents a contrarian opportunity with oversold technical conditions and positive analyst targets averaging $69, but faces significant headwinds from operational challenges in the beef business and ongoing legal investigations. Investors must weigh the attractive valuation multiples against execution risks and margin pressures in the current operating environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
